Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
- Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
May 18, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
- Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
May 17, 2021
- Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
May 17, 2021
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
May 14, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
May 14, 2021
- Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
May 13, 2021
- Novo’s Growth Hormone, Teijin’s Osteoporosis Med Skip May Listing
May 13, 2021
- May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
- Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
- Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
May 12, 2021
- Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
- Kanmin Taiwa Public-Private Confab Set for May 17
May 11, 2021
- MHLW to Fund 7 Development Projects for COVID-19 Therapies
May 11, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…